NCT05285644 - Study Evaluating the Safety and Efficacy of AR-15512 | Biotech Hunter

Enrollment

465

Participants

Timeline

Start Date

May 9, 2022

Primary Completion Date

July 24, 2023

Study Completion Date

July 24, 2023

Conditions

Dry Eye Disease

Interventions

DRUG

0.003% AR-15512 ophthalmic solution

Administered via topical ocular instillation

DRUG

AR-15512 vehicle ophthalmic solution

Inactive ingredients administered via topical ocular instillation

Trial Locations (23)

16507

Erie Retina Research, Erie

28150

Core, Inc., Shelby

33484

Segal Drug Trials, Inc., Delray Beach

37072

Advancing Vision Research, Goodlettsville

37167

Advancing Vision Research, Smyrna

38119

Total Eye Care, PA, Memphis

40206

Butchertown Clinical Trials, Louisville

46240

Michael Washburn Center for Ophthalmic Research, LLC, Indianapolis

58103

Bergstrom Eye Research, Fargo

64154

Moyes Eye Center, Kansas City

78209

Eye Clinics of South Texas, San Antonio

78229

R and R Eye Research, LLC, San Antonio

78503

Valley Retina Institute, PA, McAllen

78550

Valley Retina Institute, PA, Harlingen

78750

Austin Clinical Research, Austin

80907

Vision Institute, Colorado Springs

84015

Alpine Research Organization Inc., Clinton

89052

Center for Sight, Henderson

90027

Global Research Management, Inc, Glendale

90505

Premiere Practice Management, LLC, Torrance

97401

Verum Research, Eugene

06708

The Eye Care Group, Waterbury

04240

Central Maine Eye Care, Lewiston